2. Search Result
Search Result
Results for "

(±)-UK-88525

" in MedChemExpress (MCE) Product Catalog:

8

阻害剤およびアゴニスト

3

同位体標識化合物

製品番号 製品名 Target 研究分野 構造式
  • HY-A0033
    Darifenacin
    Maximum Cited Publications
    7 Publications Verification

    UK-88525

    		 mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin
  • HY-A0012
    Darifenacin hydrobromide
    Maximum Cited Publications
    7 Publications Verification

    UK-88525 hydrobromide

    		 mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin hydrobromide
  • HY-22437
    (±)-Darifenacin
    1 Publications Verification

    (±)-UK-88525

    		 mAChR Neurological Disease Cancer
    (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist .
    (±)-Darifenacin
  • HY-A0033S1
    Darifenacin-d4

    UK-88525-d4

    		 mAChR Cancer
    Darifenacin-d4 is the deuterium labeled Darifenacin . Darifenacin(UK88525) is a selective M3 muscarinic receptor antagonist with pKi of 8.9. IC50 value: 8.9 (pKi) .
    Darifenacin-d4
  • HY-A0012R
    Darifenacin hydrobromide (Standard)

    UK-88525 hydrobromide (Standard)

    		 Reference Standards mAChR p38 MAPK Akt Neurological Disease Metabolic Disease Cancer
    Darifenacin (hydrobromide) (Standard) is the analytical standard of Darifenacin (hydrobromide). This product is intended for research and analytical applications. Darifenacin (hydrobromide) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9. Darifenacin (hydrobromide) binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin (hydrobromide) can be used in the study of urinary incontinence and other symptoms of overactive bladder. Darifenacin (hydrobromide) inhibits tumor growth in colorectal cancer cells and has anti-tumor effects .
    Darifenacin hydrobromide (Standard)
  • HY-W746075A
    (±)-Darifenacin N-Oxide

    		mAChR Neurological Disease
    (±)-Darifenacin N-Oxide is the impurity of Darifenacin (HY-A0033). Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9 .
    (±)-Darifenacin N-Oxide
  • HY-22437S1
    (±)-Darifenacin-d4 hydrobromide

    (±)-UK-88525-d4 hydrobromide

    		 Isotope-Labeled Compounds mAChR Neurological Disease Cancer
    (±)-Darifenacin-d4 (hydrobromide) is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].
    (±)-Darifenacin-d4 hydrobromide
  • HY-22437S
    (±)-Darifenacin-d4

    (±)-UK-88525-d4

    		 Isotope-Labeled Compounds mAChR Neurological Disease Cancer
    (±)-Darifenacin-d4 is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist .
    (±)-Darifenacin-d4

オンラインお問い合わせ

入力情報は安全に管理されます. ※ 必須入力項目.

タイトル

  

国或いは地域 *

お名前 *

 

組纖名 *

デパートメント *

     

メールアドレス *

 

製品名 *

製品番号

  

カスタマ需要量 *

電話番号 *

     

必ず会社名を記載ください。個人への返信は行いません。

備考

バルクお問い合わせ

Inquiry Information

製品名:
製品番号:
数量:
MCE 日本正規代理店: